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FranceIntroduction: Chronic kidney disease (CKD) exposes to an increased incidence of fragility fractures. In-
ternational guidelines recommend performing bone mineral density (BMD) if the results will impact
treatment decisions. It remains unknown where bone loss occurs and what would preclude the longitu-
dinal loss in patients with CKD. Here, we aimed to investigate factors influencing BMD and to analyze the
longitudinal BMD changes.
Methods: In the NephroTest cohort, we measured BMD at the femoral neck, total hip, lumbar spine, and
proximal radius, together with circulating biomarkers and standardized measured glomerular filtration
rate (mGFR) by 51Cr-EDTA in a subset of patients with CKD stage 1 to 5 followed during 4.3  2.0 years. A
linear mixed model explored the longitudinal bone loss and the relationship of associated factors with
BMD changes. A total of 858 patients (mean age 58.9  15.2 years) had at least 1 and 477 had at least 2
BMD measures.
Results: At baseline, cross-sectional analysis showed a significantly lower BMD at femoral neck and total
hip and a significant higher serum parathyroid hormone (PTH) along with CKD stages. Baseline age,
gender, tobacco, low body mass index (BMI), and high PTH levels were significantly associated with low
BMD. Longitudinal analysis during the mean 4.3 years revealed a significant bone loss at the radius only.
BMD changes at the femoral neck were associated with BMI, but not CKD stages or basal PTH levels.
Conclusions: CKD is associated with low BMD and high PTH in the cross-sectional analysis. Longitudinal
bone loss occurred at the proximal radius after 4.3 years.
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KD is a global health concern because of the
increasing prevalence and cost. CKD is commonly
associated with mineral and bone disorders (MBDs),
fragility fractures, and vascular calcifications, which
substantially increase the risk of death from cardio-
vascular disease. Skeletal fractures also represent a
burden of increased morbidity, impairing the quality
of life and increasing the risk of mortality.1,2 This
increased risk of hip fracture progresses in parallel
with the decline of GFR from stage 3 to 5,3 suggesting
that bone fragility starts from early CKD-MBD and
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International Reports (2021) 6, 1525–1536The prediction of fractures in patients with CKD has
been previously based on clinical risk factors, some of
them shared with the general population, such as age,
gender, ethnicity, physical inactivity, and BMI in
addition to diabetes, cardiovascular diseases, and de-
mentia.4,5 BMD is an established good predictor of the
risk of fracture in the general population.6 In patients
with CKD, recent cumulative data and meta-analysis of
cross-sectional studies, have also demonstrated that low
BMD efficiently predicts the risk of fracture.5,7–9 This
led in 2015 to update the 2009 Kidney Disease:
Improving Global Outcomes (KDIGO) recommendations
in favor to the assessment of BMD in patients with CKD
stage 3a–5 if the result would affect treatment de-
cisions.10 BMD is also helpful in identifying patients at
high risk of fracture.11 The Fracture Risk Assessment
Tool (FRAX) has been validated in CKD populations,1525
CLINICAL RESEARCH P-E Cailleaux et al.: Longitudinal Bone Loss in CKDwhere it could either over- or underestimate the frac-
ture risk in frailty patients with CKD. Several pro-
spective studies have found that the relation between
FRAX and major osteoporotic fracture is even stronger
in patients with CKD compared with those with pre-
served renal function.3,12 However, the rate of bone
loss is not known, making it difficult to determine the
population to target and the frequency to monitor BMD
measurements.
CKD is also characterized by alteration in several
circulating biomarkers of bone metabolism including
PTH, 25-hydroxyvitamin D (25OHD), calcitriol
(1,25OH2D3), crosslaps, and total and bone-specific
alkaline phosphatases (BS-ALP).13–15 Among them, an
increase in serum PTH concentration, mainly second-
ary hyperparathyroidism, might occur early in the
course of CKD15 and is considered as a reliable surro-
gate marker to predict bone turnover and histological
changes.16 PTH concentration is also used to predict
increased risk of fracture. In hemodialysis patients,
high serum PTH levels are associated with an increased
risk of fracture17,18 and histological signs of renal
osteodystrophy.19 In early CKD stages, the slight in-
crease in PTH appears to be an appropriate adaptive
response to the progressive decline of renal function,
this occurring in order to maintain normocalcemia and
normophosphatemia as well as bone homeostasis.
However, the risk of fracture is also increased with
very low serum PTH levels.7,20 Therefore, the impact of
serum PTH levels in determining bone loss remains
unknown in patients with CKD.
When factors such as clinical, bone, and mineral
biomarkers and BMD are analyzed, PTH is constantly
found negatively correlated to BMD and bone bio-
markers.21 For instance, the highest are the serum PTH
levels, the lowest radius BMD are in cross-sectional
studies, including dialysis patients, illustrating the
importance of cortical bone loss.22–24 However, there is
a lack of longitudinal study in patients with CKD stages
3–5, in whom BMD tends to decline with the renal
impairment in parallel to the rise in serum PTH
levels.25 Of note, the KDIGO recommendation of
assessing BMD is based on data from cross-sectional
studies, but not from prospective ones. The charac-
terization of patients to target for the initial evaluation
and the monitoring remains unprecise. In addition,
evaluation of longitudinal bone loss and the value of
baseline serum PTH levels as a predictive factor remain
unresolved issues. For these reasons, we here aimed to
characterize the patient profiles by analyzing the fac-
tors that affect BMD at 4 skeletal sites, including
proximal radius, femoral neck, hip, and lumbar spine
in patients with CKD stage 1–5 participating to the
NephroTest cohort. We further assessed longitudinal1526changes in BMD related to clinical factors and serum
PTH levels.MATERIALS AND METHODS
Patients and Study Design
The NephroTest cohort is a prospective hospital-based
cohort, enrolling adult subjects older than 18 years
with any diagnosis of CKD from stage 1 to 5.26 The
cohort has been board-approved. Ambulatory patients
were referred in the Department of Nephrology and
Physiology for an evaluation of the kidney function
and mineral metabolism. They were seen annually with
an extensive set of standardized measures to assess CKD
progression and complications. Inclusions began in
January 2000. Patients were included after providing
informed consent. Exclusion criteria were pregnancy,
being on dialysis therapy, or with kidney transplants.
The patient could stop the follow-up whenever wan-
ted. A subset of 869 patients (Supplementary Figure 1),
recruited between 2005 and 2013 underwent an eval-
uation of bone metabolism including serum biomarkers
and BMD measurements as a part of the evaluation.
This study was an open cohort; the investigators were
not blinded for dual-energy X-ray absorptiometry
(DXA) results. The BMD was measured in the same
centers using the same device. We described data at
baseline from 858 patients for whom BMD was avail-
able at least at 1 skeletal site and serum PTH levels.
Among the 858 patients, 477 (55.6%) patients had 2
BMD assessments or more with a median duration of
13.2 months (12.0; 20.5) between 2 BMD measurements.
For the linear mixed effects models, among the 858
patients, we analyzed 753 patients, including 1166
visits, who had had BMD measures at all skeletal sites
(hip, which was presented as the total hip and femoral
neck, lumbar spine, and proximal radius) with no BMD
missing data at baseline. The mean duration of the
follow-up was 4.3  2.0 years.
Clinical and Biomarker Measurements
Data recorded at every visit included demographics
(age, sex, and ethnicity), the diagnosis of kidney dis-
ease, medical history (cardiovascular diseases), height
and weight, and bone-related medications. De-
terminations of blood and urinary parameters were
performed as described as follows. We assessed the
mGFR secondly standardized to body surface area, by
51Cr-EDTA renal clearance.27 Blood samples were
collected to determine the plasma levels of creatinine,
the serum levels of intact PTH, calcium, magnesium,
phosphate, ionized calcium, 25OHD, albumin, uric
acid, calcitriol, total alkaline phosphatase, BS-ALP, and
serum crosslaps.Kidney International Reports (2021) 6, 1525–1536
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kinetic Jaffe colorimetric method on a Bayer RA-XT
then a Konelab 20 analyzer (ThermoFisher Scientific,
Waltham, MA) from the study start to 2008 and an
enzymatic assay (KoneLab; Thermo Fisher Scientific)
thereafter. Serum PTH concentrations were measured
by second-generation 2-site radio-immunometric assay
(Allegro-Intact PTH; Nichols Institute Diagnostics, San
Clemente, CA), and by chemoluminescent assay (from
January 2004 onward, Elecsys Roche [Indianapolis, IN]
[normal values 10–65 pg/ml]). Total calcium and mag-
nesium concentrations were measured by atomic ab-
sorption spectrophotometric method in plasma
(Siemens, Munich, Germany). Normal values range
from 2.12 to 2.52 for serum calcium and from 0.75 to
1.03 for magnesium. Phosphate concentration was
measured by colorimetry in plasma (phosphomolybdate
assay [normal values 0.81–1.58 mmol/l]) and ionized
calcium by a specific electrode in serum (normal values
1.15–1.30 mmol/l). Plasma 25OHD concentration was
measured by a radioimmunologic method (DiaSorin,
Saluggia, Italy) that recognized both 25OHD2 and D3
with similar affinity. Plasma albumin was measured
using colorimetry. Uric acid concentrations were
measured by enzymatic methods (normal values 200–
420 mmol/l). Serum 1,25OH2D was measured using a
radioimmunologic method (Immunodiagnostic Systems,
Tyne & Wear, UK, www.idsplc.com) with reference
values 20 to 60 pg/ml. We measured total alkaline
phosphatase concentration by an enzymatic method
(Siemens, [normal values 50–136 UI/l]) and BS-ALP by a
radioimmunometric assay (Tandem-R, Ostase, Hybri-
tech Europe SA, Brussels, Belgium, reference range,
4.0–25.0 ng/ml). Serum crosslaps were measured using
an immunoradiometric assay (Osteometer Biotech S/A,
Herlev, Denmark). Reference values were less than 658
pg/ml (5.1 nmol/l) for premenopausal women and men
and less than 580 pg/ml (4.5 nmol/l) for menopausal
women. The BS-ALP and the crosslaps were measured
in a subset of 597 patients: 96 with 1–2 CKD stages, 147
with 3a CKD stages, 177 with 3b stages and in 177
patients with 4–5 CKD stages. We also measured pro-
teinuria in the urine by colorimetry (pyrogallol red
with molybdate). Urinary albumin was measured using
solid-phase fluorescent immunoassays and expressed as
urinary albumin-creatinine ratio.
BMD Measurements
BMD was measured by DXA and performed per pro-
tocol once a year, using either a Hologic QDR4500A
Scanner (Hologic, Bedford, MA) in one center or an
iDXA device (GE Medical Systems Lunar, Madison, WI)
in a second center, for the whole duration of the study
operated with the same technician and with only 1Kidney International Reports (2021) 6, 1525–1536referent physician for analysis per center. BMD was
measured at the femoral neck, at the hip, at the lumbar
spine, and at the proximal radius. We assessed the areal
BMD (g/cm2), Z-scores and T-scores using the National
Health and Nutrition Examination Survey reference
population. We also used the World Health Organiza-
tion definitions of BMD categories: normal bone den-
sity (T-score $ 1), low bone mass (T-score
between 1.0 and 2.5), and osteoporosis (T-
score # 2.5). Results are presented in accordance
with the guidelines issued by the International Society
for Clinical Densitometry. Stability of the measure-
ments was checked every day, using a phantom for
calibration. The mean coefficient of variation for mea-
surement of the patients was as follows: lumbar spine,
0.41%; total hip, 0.53%; femoral neck 1.36%; and
radius 1.22%. Cross-calibration equations to stan-
dardized BMD measures have been used in the
description of the population,28–31 except from the
proximal radius, stratified by center. The mean least
significant change for measurement of the patients was
as follows: lumbar spine, 1.14%; total hip, 1.47%;
femoral neck 3.77%; and radius 3.38%.
Statistical Analysis
Data were presented as mean ( SD) and median and
interquartile range when needed. We performed Bar-
tlett’s test to compare variances between each CKD
stage. In case of homoscedasticity, an analysis of vari-
ance was conducted following by a Tukey’s test as a
posteriori multiple comparison when applicable
(respectively, if heteroscedasticity, a Kruskal-Wallis
test has been performed, following by a Steel-Dwass-
Critchlow-Fligner test when applicable).
Four linear mixed models were performed as the
BMD was measured at all skeletal sites (femoral neck,
hip total, lumbar spine, and proximal radius). The
linear mixed model requires neither the same number
of BMD measurements per patient, nor that these
measurements have been taken at the same time points
for all patients. This also allows accounting for patients
with only 1 BMD measurement at baseline to reduce
selection bias.32 Baseline PTH was considered as a
continuous parameter. The covariables included in our
models were those known as to be involved in BMD:
age, BMI (coded as “<25 kg/m2” vs. “$25 kg/m2”),
gender (including the menopausal status for women),
ethnicity (coded as “black origin” or not), tobacco use
(coded as “never smoking,” “former smoker,” or
“current smoker”). The other variables included as
adjustment variables were mGFR expressed as CKD
stage classes (1–2, 3a, 3b, and 4–5), PTH (pg/ml),
treatments that interfere with bone (corticosteroid or
bisphosphonates) and those that interfere with PTH1527





1 - 2 3a 3b 4 - 5
P value
‡ 60 ml/min 45-60 ml/min 30-45 mL/min < 30 mL/min
n ¼ 156 n ¼ 203 n ¼ 262 n ¼ 237
Age (yr) 58.915.2 50.815.7 59.813.2 61.114.8 61.115.1 0.061
Weight (kg) 75.516.5 74.617.1 74.515.1 75.416.8 77.118.1 0.339
Height (cm) 167.69.2 168.78.4 168.28.8 166.99.7 167.09.6 0.134
Intact PTH (pg/ml)a 57.0(38.0;90.0) 37.0(26.0;48.2) 48.0(34.5;66.5) 62.0(43.0;89.8) 101.0(68.0;164.0) < 0.001
ionized calcium (mmol/l)a 1.23(1.20;1.27) 1.23(1.20;1.26) 1.23(1.21;1.27) 1.23(1.21;1.27) 1.24(1.20;1.27) 0.87
serum calcium (mmol/l)a 2.27(2.20;2.34) 2.27(2.21;2.34) 2.28(2.22;2.35) 2.27(2.21;2.34) 2.25(2.17;2.32) < 0.01
corrected calcium (mmol/l)a 2.29(2.23;2.37) 2.27(2.21;2.33) 2.28(2.24;2.37) 2.31(2.24;2.37) 2.29(2.21;2.37) < 0.05
serum magnesium (mmol/l)a 0.79(0.73;0.85) 0.77(0.73;0.82) 0.78(0.73;0.84) 0.79(0.74;0.84) 0.81(0.74;0.88) < 0.05
serum phosphate (mmol/l) 1.05(0.93;1.17) 1.02(0.90;1.13) 0.99(0.89;1.09) 1.03(0.93;1.14) 1.15(1.03;1.34) < 0.001a
25(OH)-vitamin D (ng/ml) 21.912.2 20.911.5 22.811.2 22.713.1 21.012.2 0.066b
Calcitriol (pg/ml)a 20.0(12.5;28.8) 43.2(31.0;55.2) 36.2(27.5;45.7) 31.0(22.9;40.4) 21.7(15.0;30.0) < 0.001
BS-ALP (ng/ml)a 13.6(10.1;18.4) 13.4(10.2;17.8) 13.7(10.2;17.5) 13.7(10.1;19.4) 13.3(10.0;19.2) 0.824
uric acid (mmol/l) 405.799.8 354.883.3 399.891.8 423.497.5 424.4106.9 < 0.001b
serum crosslaps (nmol/l)a 516.1(258.1;774.2) 258.1(258.1;387.1) 387.1(258.1;645.2) 516.1(258.1;645.2) 774.2(387.1;1064.5) < 0.001
CKD, chronic kidney disease; mGFR, measured glomerular filtration rate; PTH, parathyroid hormone; BS-ALP, bone specific alkaline phosphatases.
Results are expressed as meanstandard deviation. An ANOVA was conducted following by a Tukey’s test as a posteriori multiple comparisons when p-value <0.05
aMedian (25th through 75th percentile) compared by a Kruskall-Wallis’ test following by a Steel-Dwass-Critchlow-Fligner’s test. as a posteriori multiple comparisons when P value <0.05.
bAnalysis of variance test with log transformation of the variable.
CLINICAL RESEARCH P-E Cailleaux et al.: Longitudinal Bone Loss in CKDmetabolism (diuretic drugs, lithium, or calcitriol). All
these factors were those collected at baseline, meaning
at the first BMD examination. Time has been calculated
as time span between the considered BMD examination
and the first BMD examination. As fixed effects, we
entered ethnicity, tobacco use, bone treatment, and
PTH treatment. Considering the potential effect of PTH
on BMD in different groups, we introduced this factor
and its interaction terms with age and gender. Time has
been introduced in the model with interaction terms
with PTH, BMI, and mGFR (i.e., CKD stages). As
random effects, we had intercepts for subjects as well
as by-subject random slopes for the effect of time.
Random effects allow accounting for correlation be-
tween measurements of a same patient and also for
variability of each patient around mean trajectory. We
also entered the factor center to have all the data
collected and grouped from the 2 relevant centers. We
supposed a linear evolution of BMD measurements over
time since a quadratic form of time did not fit the data
better. Visual inspection of residual plots did not reveal
any obvious deviation from homoscedasticity or
normality. The lmerTest package provides P values for
fixed effects in type III analysis of variance and sum-
mary tables via Satterthwaite’s degrees of freedom
method. As a sub-analysis, to visualize the BMD evo-
lution along time according to baseline PTH classes, we
divided the values of PTH in low (#65 pg/ml), normal
(65–129 pg/ml), or high PTH (>129 pg/ml). All tests
were 2-sided and significance level fixed at 0.05. As
statistical software, we used STATA/IC 16.0 (Stata-
Corp., College Station, TX) and R version 3.5.1 (2018-
07-02, The R Foundation for Statistical Computing,1528Vienna, Austria) to estimate linear mixed models33
(lme4 package 1.1–21).
To compare our results with previous studies, we
also modeled BMD change over time (difference be-
tween first and last measurement divided by follow-up
time) using a linear model. This analysis was thus
restricted to patients with at least 2 BMD
measurements.RESULTS
Patient Characteristics at Baseline
The 858 patients were issued from the NephroTest
cohort that has been described previously
(Supplementary Figure 1). The mean age was 58.9 
15.2 years, 67% were men, 70.8% postmenopausal
women, and the mGFR was 43.0  19.5 ml/min
(Table 1). Patients from sub-Saharan Africa or the
French West Indies (15.8%) were also included. The
mean BMI was 26.8  5.3 kg/m2.
Among them, 156 (18.2%) had an mGFR more than
60 ml/min per 1.73 m2 (1.7% stage 1 and 16.4% stage
2). In 657 subjects (76.6%), mGFR was between 15 and
60 ml/min per 1.73 m2, including 23.7% stage 3a,
30.5% 3b, and 22.4% stage 4, respectively. Finally, 45
patients had an mGFR less than 15 ml/min per 1.73 m2
(5.2% stage 5 CKD). No patients on dialysis therapy or
transplanted were included.
The most common comorbidity was hypertension
(91%), followed by diabetes mellitus (25.2%) and car-
diovascular diseases (16.1%). Most represented ne-
phropathies were vascular nephropathy (18.2%),
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Figure 1. Cross-sectional analysis of biochemical parameters according to chronic kidney disease (CKD) stages. (a) Baseline serum total
calcium and total phosphate concentrations. (b) Baseline intact parathyroid hormone (PTH) concentrations.
P-E Cailleaux et al.: Longitudinal Bone Loss in CKD CLINICAL RESEARCHnephropathy (9%), diabetic nephropathy (8.5%),
polycystic kidney disease (5.9%), or otherwise not
determined (53.6%). The history of drugs interfering
with bone metabolism found a large use of diuretics
(46.2%, including 24.5% loop diuretics and 22.1%
thiazide diuretics), 28.2% were receiving phosphate-
calcium regulatory medications, 14.7% were under
vitamin D supplementation, 9.9% were under calcitriol
therapy, but only 7.2% currently having corticoste-
roids and 2.1% bisphosphonates.
Cross-sectional Analysis of Biochemical and
BMD Indices
Baseline biochemical characteristics are shown in
Table 1. We found a mild but significant decrease in
concentrations of serum total calcium (P < 0.01,
Figure 1a) and a significant increase of phosphate (P <
0.001, Figure 1a) along with a significant increase of
PTH throughout CKD stages (P < 0.001, Figure 1b).
Serum PTH concentrations were above the normal
range (65 pg/ml) in 370 patients (43.1%) of which 4
were associated with a hypercalcemia suggesting a
primary hyperparathyroidism. A borderline significant
difference in circulating 25OHD concentrations was
found according to CKD severity. Mean concentrations
at each CKD stage revealed vitamin D insufficiency.
Concentrations of 25OHD were #10 ng/ml (25 nmol/l)
in 17.1% patients, between 10 and 20 ng/ml (25–50
nmol/l) in 33.3% patients, between 20 and 30 ng/ml
(50–75 nmol/l) in 27.4% patients and above 30 ng/ml
(75 nmol/l) in 22.2% patients. Calcitriol levels
decreased significantly with kidney failure (P < 0.001).
Serum crosslaps levels are significantly higher in CKD
stages 4–5 (P < 0.001), whereas BS-ALP remained
normal at any stage. Associations of mGFR with other
markers of mineral and bone metabolism in the whole
cohort have been previously detailed.15Kidney International Reports (2021) 6, 1525–1536Table 2 shows the prevalence of osteopenia and
osteoporosis at all sites and for any CKD stages. Indeed,
46% to 66% had a T-score above 1 SD, whereas T-
score was below 2.5 SD in 10% to 14% throughout
the CKD stages. Moreover, BMD was significantly
lower with advanced CKD stages at the femoral neck
(P < 0.0001), total hip (P < 0.001), and at lumbar spine
(P < 0.05 Figure 2). At the proximal radius, BMD was
significantly lower in late CKD stages (P < 0.05) with
the Hologic DXA device, but not with the GE-Lunar
device.
Association Between Clinical Factors and
Serum PTH Levels for BMD at Baseline
The final linear mixed effect models included age,
gender, ethnicity, and tobacco use without interaction
terms with duration of follow-up and BMI, PTH, and
CKD stages with interaction terms with time of follow-
up. Head of Table 3 shows the effects of variables at
baseline for BMD measured at the femoral neck. After
adjustment, there is a strong negative association with
age; the higher is the age the lower is the BMD. A
significant negative association was also found with
gender; compared with men, premenopausal women
had a mean BMD lower (by 0.0481 g/cm2; 95%
CI 0.0833 to 0.0130) and a further reduction in
postmenopausal women (by 0.0849 g/cm2; 95%
CI 0.1082 to 0.0617). BMD was negatively impacted
in advanced CKD stages (3b to 4–5). In contrast, high
BMI and African ethnicity were positively associated
with BMD. The adjusted baseline PTH had a negative
relationship with BMD at the femoral neck (estimated
effect ¼0.023, P < 0.01). At the radius site, BMD was
negatively associated with age, gender, and tobacco
use, whereas ethnicity, CKD stages, and PTH levels had
no significant impact (Table 4). Considering baseline
BMD at the total hip and at the lumbar spine, we found1529






1 - 2 3a 3b 4 - 5
P value
‡ 60 ml/min 45-60 ml/min 30-45 ml/min < 30 ml/min
n ¼ 156 n ¼ 203 n ¼ 262 n ¼ 237
Femoral neck BMD (g/cm2) 0.870.16 0.94  0.17 0.89  0.15 0.87  0.16 0.83  0.14 <0.0001
Z-score 0.201.08 0.401.16 0.301.08 0.261.04 -0.111.00 <0.0001
T-scorea -0.9(-1.7;-0.01) -0.28(-1.10;0.70) -0.80(-1.60;0.10) -1.00(-1.70;-0.06) -1.28(-1.91;-0.53) <0.0001
Total hip BMD (g/cm2) 0.97.017 1.02  0.17 0.98  0.17 0.96  0.17 0.93  0.16 <0.0001
Z-score 0.391.11 0.501.12 0.461.08 0.461.13 0.181.10 <0.05
T-score -0.251.22 0.201.29 -0.171.20 -0.291.21 -0.551.12 <0.0001
Lumbar spine BMD (g/cm2) 1.080.18 1.09  0.17 1.11  0.19 1.08  0.19 1.05  0.18 <0.05
Z-score 0.111.54 -0.121.42 0.361.47 0.201.58 -0.061.59 <0.01
T-score -0.481.58 -0.381.50 -0.251.59 -0.491.66 -0.731.48 <0.05
Proximal radius
Hologic BMD (g/cm2) 0.50  0.12 0.51  0.11 0.51  0.10 0.50  0.13 0.50  0.12 0.764b
Z-score 0.59  1.42 0.48  1.36 0.66  1.37 0.72  1.46 0.44  1.45 0.318
T-score -0.60  1.52 -0.46  1.51 -0.51  1.48 -0.54  1.60 -0.77  1.47 0.357
GE-Lunar BMD (g/cm2) 0.89  0.12 0.91  0.11 0.91  0.12 0.88  0.12 0.85  0.15 <0.05
Z-score -0.31  1.08 -0.49  0.98 -0.12  0.99 -0.26  1.11 -0.35  1.23 0.219
T-score -0.76  1.13 -0.57  1.07 -0.61  1.01 -0.87  1.15 -1.03  1.25 <0.05
Bone statusc normal (n, %) 473 (56%) 104 (66%) 122 (61%) 139 (53%) 108 (46%) <0.01d
osteopenia (n, %) 283 (33%) 37 (24%) 59 (29%) 94 (36%) 93 (40%)
osteoporosis (n, %) 96 (11%) 15 (10%) 20 (10%) 28 (11%) 33 (14%)
CKD, chronic kidney disease; BMD, bone mineral density; mGFR, measured glomerular filtration rate.
Results are expressed as mean  SD. An analysis of variance was conducted following by a Tukey’s test as a posteriori multiple comparisons when P value <0.05
aMedian (25ththrough 75thpercentile) compared by a Kruskall-Wallis test following by a Steel-Dwass-Critchlow-Fligner test as a posteriori multiple comparisons when P value <0.05.
bAanlysis of variance test with log transformation of the variable.
cAccording to World Health Organization definition including T-score at L1-L4 and Total Hip.
dChi-square test.
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(Supplementary Tables S1 and S2). Spinal BMD was
negatively associated with female gender and baseline
PTH levels. Altogether, age, gender, BMI, and PTH are
significant influencing factors for BMD.
Analysis of Longitudinal Changes in BMD
During the mean follow-up of 4.3 years, there was a
slight, but significant reduction in mGFR throughout































Figure 2. Baseline standardized bone mineral density (BMD) throughout c
energy X-ray absorptiometry in 858 patients. Results are presented as bas
CKD stages. For each skeletal site, an analysis of variance was conducte
*P < 0.05, ** P < 0.01, ***P < 0.001.
15301.73 m2 from baseline to 1.5, 3.0, and 4.5 years,
respectively (P < 0.0001). On average, mGFR decreased
by 1.2 mL/min per year. Longitudinal data revealed a
significant BMD loss only at the radius throughout time
(Table 4). Over follow-up, no significant change in
BMD occurred at the femoral neck, total hip, and spine
(Table 3, Supplementary Tables S1 and S2), and no
factor was associated with the evolution of BMD at the
radius, total hip, and spine (Table 4, Figure 3a,
























hronic kidney disease (CKD) stages. BMD was measured using dual-
eline BMD at the femoral neck (a) and the spine (b) according to the
d following by a Tukey’s test as a posteriori multiple comparisons.
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Table 3. Estimated adjusted effects of variables on mean femoral neck BMD at baseline and BMD change over 4.3 years follow-up (n ¼ 753
patients, 1166 visits)
Variable Estimated effect 95% CI P value
Mean difference of BMD at baseline
Age at baseline (y) -0.0037 -0.0044 to -0.0029 < 0.0001
Gender
Men Ref. < 0.0001
Premenopausal women at baseline -0.0481 -0.0833 to -0.0130
Postmenopausal women -0.0849 -0.1082 to -0.0617
BMI at baseline (kg/m2)
<25 Ref. < 0.0001
$25 0.0894 0.0703 to 0.1086
Ethnicity
No African origin Ref. < 0.0001
African origin 0.0746 0.0486 to 0.1008
Tobacco use at baseline
Never smoking Ref. 0.060
Former smoker -0.0036 -0.0254 to 0.0179
Current smoker -0.0341 -0.0626 to -0.0059
CKD stages at baseline
1-2 Ref. < 0.01
3a -0.0171 -0.0458 to 0.0113
3b -0.0313 -0.0598 to -0.0030
4-5 -0.0575 -0.0894 to -0.0257
log(PTH) at baseline -0.0230 -0.0391 to -0.0069 < 0.01
Mean BMD change
Time (yrs) -0.0023 -0.0127 to 0.0082 0.677
BMI at baseline (kg/m2)
<25 Ref. <0.05
$25 0.0031 0.0002 to 0.0060
CKD stages at baseline
1-2 Ref. 0.099
3a -0.0014 -0.0066 to 0.0037
3b -0.0045 -0.0096 to 0.0005
4-5 -0.0004 -0.0060 to 0.0052
log(PTH) at baseline -0.0005 -0.0032 to 0.0022 0.704
BMD, bone mineral density; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; PTH: parathyroid hormone.
The factor center has been included as random effect
P-E Cailleaux et al.: Longitudinal Bone Loss in CKD CLINICAL RESEARCHthe femoral neck is positively impacted in subjects
with higher BMI, whereas it is not influenced by CKD
stages (Figure 3b).
When baseline serum PTH concentrations were
considered in the lowest (0–65), normal (1–2 fold: 65–
129) or highest (>129 pg/ml) ranges, BMD changes
were similar regardless of PTH classes at the radius and
femoral neck (Supplementary Table S3, Supplementary
Figure S1).
We also performed a linear model as a sensitivity
analysis. We included the factors used in the mixed
model that could affect the annualized BMD changes
(Supplementary Table S4). This showed that no factor
at baseline is involved in BMD changes.DISCUSSION
The results of this prospective study from the Neph-
roTest cohort, a well-characterized population ofKidney International Reports (2021) 6, 1525–1536patients with CKD with mGFR, showed a lower BMD
with the progression of CKD. At any skeletal sites,
BMD was negatively associated with clinical factors,
including age, female gender regardless of menopause,
current tobacco use, and with baseline serum PTH
levels. In contrast, higher BMI, African ethnicity, and
higher mGFR (expressed as CKD stages) are associated
with higher BMD. The study provides several new
findings. First, T-score and Z-score BMD were
above 1 SD at any skeletal sites and at any stage of
CKD. This might be related in part to the population
that was mostly composed of men at their mid-age. The
prevalence of osteoporosis was between 10% and 14%
and increased slightly according to the CKD stages.
Second, longitudinal BMD loss could be detected only
at the proximal radius after 4.3 years of follow-up and
independently of baseline CKD stages and PTH classes.
Here, the cross-sectional analysis showed a lower
BMD at the lumbar spine or the total hip in relation to1531
Table 4. Estimated adjusted effects of variables on mean radius BMD at baseline and BMD change over 4.3 years follow-up (n ¼ 753 patients,
1166 visits)
Variable Estimated effect 95% CI P value
Mean difference of BMD at baseline
Age at baseline (y) -0.0017 -0.0023 to -0.0012 < 0.0001
Gender
Men Ref. < 0.0001
Premenopausal women at baseline -0.0941 -0.1216 to -0.0666
Postmenopausal women -0.1277 -0.1459 to -0.1095
BMI at baseline (kg/m2)
<25 Ref. < 0.001
$25 0.0270 0.0119 to 0.0422
Ethnicity
No African origin Ref. 0.204
African origin 0.0134 -0.0071 to 0.0339
Tobacco use at baseline
Never smoking Ref. 0.088
Former smoker -0.0184 -0.0353 to -0.0014
Current smoker -0.0002 -0.0224 to 0.0220
CKD stages at baseline
1-2 Ref. 0.467
3a 0.0171 -0.0056 to 0.0397
3b 0.0053 -0.0173 to 0.0279
4-5 0.0059 -0.0194 to 0.0311
log(PTH) at baseline -0.0107 -0.0234 to 0.0021 0.105
Mean BMD change
Time (y) -0.0158 -0.0292 to -0.0023 <0.05
BMI at baseline (kg/m2)
<25 Ref. 0.545
$25 -0.0011 -0.0048 to 0.0025
CKD stages at baseline
1-2 Ref. 0.951
3a 0.0012 -0.0054 to 0.0078
3b 0.0007 -0.0058 to 0.0073
4-5 -0.0002 -0.0075 to 0.0070
log(PTH) at baseline 0.0030 -0.0004 to 0.0065 0.089
BMD, bone mineral density; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; PTH, parathyroid hormone.
The factor center has been included as random effect.
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dividuals of the MrOS study.34,35 These findings might
reinforce the KDIGO recommendations of assessing
BMD in the CKD population. The consistent findings of
normal Z-score at all skeletal sites makes unlikely the
contribution of the calcifications of abdominal aorta in
lumbar BMD measures, given that the other sites were
also normal. Our data also confirmed the progressive
increase in serum PTH concentrations along with the
severity of CKD; this occurring in order to maintain
serum calcium and phosphate within normal ranges.
Indeed, BMD at lumbar spine, total hip, and femoral
neck was negatively correlated with PTH
(Supplementary Table S2), therefore high serum PTH
concentrations might mediate low BMD at several
skeletal sites despite a differential PTH effect on
cortical and trabecular bone as previously reported.22
We also observed a high proportion of patients with
CKD with vitamin D insufficiency, whereas KDIGO1532guidelines recommend maintaining circulating 25OHD
levels above 30 ng/ml.10,11 The low serum 25OHD
concentrations in most severe patients with CKD could
favor and amplify the risk of secondary hyperpara-
thyroidism, resulting in an increased bone resorption
and cortical bone loss.36,37 Serum crosslaps, a bone
resorption marker, were increased in late stages; this
might be related to impaired renal function. In
contrast, serum BS-ALP levels, a bone formation
biomarker independent of renal impairment, were sta-
ble, as reported previously in patients with end-stage
CKD to be higher before the initiation of hemodialysis
therapy.38–40 These apparently controversial results
might illustrate the differential clearance of these bio-
markers; BS-ALP clearance being unaffected by renal
impairment.
Here, we did not aim either to identify specifically
osteoporosis in CKD-MBD especially in advanced CKD,














































Figure 3. Mean changes of bone mineral density (BMD) throughout time according to baseline chronic kidney disease stages at (a) the radius
and (b) the femoral neck.
P-E Cailleaux et al.: Longitudinal Bone Loss in CKD CLINICAL RESEARCHchanges in BMD. A major finding of this study was that
the longitudinal bone loss observed in patients with
CKD was restricted to the proximal radius, whereas
BMD remained stable at the femoral neck, total hip, and
lumbar spine. These data invite better definition of the
skeletal site and the monitoring schedule of serial BMD
measurements in patients with CKD. Here, the lack of
longitudinal bone loss at other skeletal sites than the
proximal radius after 4.3 years might be due to the
male gender, most participants being men in agreement
with the initial recruitment design (hypertension and
CKD workup). In addition, we cannot exclude that the
BMD decline is not linear, as suspected in the Rancho
Bernardo study,41 the long-term evaluation would
require longer monitoring. Because subtle trabecular
and cortical bone changes may occur but cannot be
caught by DXA BMD measures, it will be interesting to
investigate the changes of BMD and microarchitecture
with high-resolution peripheral computed tomogra-
phy, which may broaden the understanding and dif-
ferential role of PTH on trabecular and cortical bone.
Baseline high serum PTH levels are negatively
associated with low BMD at all skeletal sites in cross-
sectional analysis, this confirming several previous
data. However, our results show that neither baseline
nor changes in serum PTH levels are associated with
BMD changes at any skeletal site in patients with CKD
despite the reduction of mGFR. Stratification accordingKidney International Reports (2021) 6, 1525–1536to 3 PTH classes showed that each PTH group experi-
enced identical bone change over time at any site. One
might hypothesize that the deleterious effect of PTH on
the skeleton might require a time longer than 4.3 years
to be captured or occurs at an early stage of CKD.
Indeed, analyzing a cohort of patients with CKD stages
2–3b with a mean age of 70 to 79 years for 11 years,
serum PTH was linked to BMD, but no longitudinal
bone loss was observed despite an older age.9 A
retrospective study based on 374 patients followed for
5 years and selected on BMD availability also failed to
show the impact of PTH on BMD.42 Data from the CKD-
DOPPS cohort show that although monitoring of CKD-
MBD laboratory markers is consistent with the guide-
lines in many countries, the target levels for many
parameters notably vary, and treatment of mineral
disorders is generally poor in patients with CKD.43
Indeed, the revised KDIGO recommendations might
be weighted when suggesting that treatment should be
based on sequential measurements of PTH, but not
only on a single elevated serum PTH level.
Here, we could not assess whether baseline serum
PTH levels could predict the risk of skeletal fractures
because of the lack of data collection. In hemodialysis
patients, high PTH is associated with increased risk of
fracture,17,18 but this risk is also observed with very
low PTH levels.7,20 A large prospective database
including 5100 subjects with CKD stages 3–4 showed1533
CLINICAL RESEARCH P-E Cailleaux et al.: Longitudinal Bone Loss in CKDthat PTH was an independent factor predictive of
fractures, low PTH having a protective effect.44
Moreover, the reduction of PTH by calcimimetics as
in the EVOLVE (EValuation Of Cinacalcet HCl Therapy
to Lower CardioVascular Events) trial and using an
unadjusted intention-to-treat analysis, showed that
cinacalcet did not reduce the rate of clinical fracture.
However, when accounting for differences in baseline
characteristics of multiple fractures, and/or events
prompting discontinuation of study drug, cinacalcet
reduced the rate of clinical fracture by 16% to 29%.45
Therefore, these controversial results leave the issue of
PTH levels and fracture risk unresolved.
The main strengths of this study are the standardi-
zation of the mGFR, the large sample of patients, and
the monitoring of the follow-up in the cohort. The
study has also some limitations, including that the
patients were not naïve of treatment at the inclusion of
the study. This might have introduced a bias, although
2% of the patients were receiving bisphosphonates at
the inclusion. We have no information if this was
changed during the follow-up, and subsequently might
have affected DXA results. Also, the lack of exploitable
fracture data collected at each visit should be
mentioned. Fibroblast growth factor 23 and klotho
were not systematically assessed at the beginning of the
cohort, the lack of data to achieve a workable outcome.
The vitamin D insufficiency in late stages cannot be
linked to self-report vitamin D uptake, to explore if
there was a lack of vitamin D prescription in these
patients. Understanding CKD-MBD and its evolution in
nondialysis patients remains partial and noninvasive
tools provide limited information in bone metabolism
and structure. The need for stronger and more specific
biomarkers will help in the global understanding of
CKD-MBD.
In conclusion, clinical factors and baseline high
serum PTH levels are associated with a low BMD in
CKD stages 1–5, then allowing identifying patients
with CKD who require BMD measures. Longitudinal
analysis shows a bone loss only at the proximal radius,
and no predictive value of baseline factors on BMD loss
through a period of 4.3 years at any skeletal site,
suggesting that monitoring BMD every 4 years could
be sufficient. BMD remains stable for 3 classes of PTH,
rendering it difficult to establish an optimal PTH value
associated with normal BMD in patients with CKD.KEY FINDINGS
In patients with CKD stages 1–5, age, gender, ethnicity,
BMI, and serum PTH levels are associated with BMD at
all skeletal sites. Longitudinal analysis showed a BMD
loss only at the radius after a mean 4.3 years of follow-1534up. In middle-aged patients with CKD, we recommend
BMD measures specifically using clinical profile and
serial BMD measurements, including the radius, every
4 years.DISCLOSURE
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